https://www.selleckchem.com/pr....oducts/CP-690550.htm
Purpose Rivastigmine hydrogen tartrate (RHT) is commonly used for the treatment of mild to moderate Alzheimer's disease (AD). The aim of this work was to formulate in-situ pluronic F-127 (PF-127) hydrogels containing Eudragit RL-100 (EU-RL) nanoparticles (NPs) in order to improve the therapeutic efficacy of RHT through the nasal route. Methods The NPs were prepared using different polymer to drug ratios and evaluated for their physicochemical characteristics, cellular uptake and in vitro cytotoxicity against lung adenocarcinoma cells
Like
Comment
Share
